02092-A: Developing the Use of a Novel Imaging Technique to Define a Dog's Potential Responsiveness to Chemotherapy

Grant Status: Closed

Grant Amount: $12,733
Michael O. Childress, DVM, MS; Purdue University
December 1, 2013 - November 30, 2014

Sponsor(s): American Belgian Tervuren Club, Inc., American Brittany Club, Bernese Mountain Dog Club of America, Boykin Spaniel Club and Breeders Association of America, Clumber Spaniel Club of America, Clumber Spaniel Health Foundation, Collie Health Foundation, Finnish Lapphund Club of America, Inc., Hip Dysplasia DAF, National Beagle Club, Norwegian Elkhound Association of America, Inc., Orthopedic Foundation for Animals, Pug Dog Club of America, Inc., Rottweiler Health Foundation, Staffordshire Terrier Club of America, Tibetan Terrier Club of America/Tibetan Terrier Health & Welfare Foundation, United States Australian Shepherd Association, United States Australian Shepherd Foundation

Breed(s): -All Dogs
Research Program Area: Oncology - Lymphoma
Donate to Support this Research Program Area


Lymphoma is one of the most common cancers in pet dogs. Although this cancer responds well to chemotherapy, the duration of cancer remission and survival time afforded by chemotherapy differ dramatically from dog to dog, with some dogs' cancers responding less favorably to chemotherapy than others. Unfortunately, there are no current tests that can predict the response of an individual dog's cancer to chemotherapy. A method to accurately predict the likelihood and duration of cancer remission provided by specific chemotherapy drugs would be extremely valuable for identifying those dogs most likely to benefit from chemotherapy and for selecting the best drugs to treat individual dogs' cancers. This would allow "personalized" treatment for individual dogs with lymphoma. Dr. Childress will test a new technology called biodynamic imaging (BDI) for its ability to predict the response of canine multicentric lymphoma to doxorubicin, the most potent chemotherapy drug for treating this cancer. BDI data will be compared with clinical response to chemotherapy to determine how well BDI predicts the likelihood and duration of cancer remission. The study results study will be used to plan larger follow-up studies to further develop BDI as a method for personalizing chemotherapy treatment for dogs with lymphoma.


Custead, M. R., An, R., Turek, J. J., Moore, G. E., Nolte, D. D., & Childress, M. O. (2015). Predictive value of ex vivo biodynamic imaging in determining response to chemotherapy in dogs with spontaneous non-Hodgkin’s lymphomas: a preliminary study. Convergent Science Physical Oncology, 1(1), 015003. https://doi.org/10.1088/2057-1739/1/1/015003

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Connect With Us:
Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617

Tax ID# 13-3813813

   2020 GuideStar logo

© 2020 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software